Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2013

Pharmacy Update: Xeljanz (tofacitinib) Requires Prior Authorization 

Recently, the FDA approved Xeljanz (tofacitinib) tablets for the treatment of moderate-to-severe active rheumatoid arthritis in adults who haven’t been helped by or who can’t take the medication methotrexate. Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints and surrounding tissue.

Xeljanz may be used alone or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDS). However, Xeljanz should not be used in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine.

Xeljanz works differently from other rheumatoid arthritis medications; it inhibits the Janus kinase (JAK) pathway, a signaling pathway inside cells that plays an important role in the inflammation involved in rheumatoid arthritis.

Xeljanz requires a prior authorization to ensure its use as a second line therapy and only with an appropriate diagnosis. Xeljanz is available through Curascript specialty pharmacy. For information, visit Harvard Pilgrim’s pharmacy page.

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version


Final Reminder: Please Return Completed Medicare Advantage Contracts

Provider Claim Reporting Update

New Product Offering: NorthStar Preferred Care Plan


Pharmacy Update: Xeljanz (tofacitinib) Requires Prior Authorization

Policy Update: Hizentra and Immune Globulin

Assessing Suicide Risk in the Primary Care Setting


Payment Policy Update: Positron Emission Tomography (PET) Scans

Payment Policy Update: Refraction Services

Payment Policy Update: Anesthesiology

Pricing for Molecular Pathology Codes

2013 Fee Schedule Updates

Policy Reminder: HCPCS Level II C codes


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network and Product Development

Joann Peck,
Manager, Network Planning and Administration

Annmarie Dadoly,

Kristin Edmonston,
Production Coordinator